Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT1061250057) titled 'Clinical Study to Evaluate the Antitumor Effect of Perampanel in Patients with Lower-Grade Glioma' on Oct. 1.
Study Type: Interventional
Study Design:
single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
Primary Sponsor: Ozono Iori
Condition:
Adult-type diffuse glioma, CNS WHO grade 2-3
glioma, astrocytoma, oligodendroglioma
D005910
Intervention:
Administration of Fycompa (tablet, dry syrup, or intravenous formulation
Recruitment Status: Recruiting
Phase: 2
Date of First Enrollment: 01/10/2025
Target Sample Size: 20
To know more, visit https://jr...